Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2022-11-14 00:00:00 ET · period of report 2022-11-11 · accession 0001209191-22-056581 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-14 | 2022-11-11 | CBIO | Semerjian Harout | CEO, Dir | P - Purchase | $1.29 | +25.0K | 25.0K | New | +$32.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-11 | P | A | 25,000 | $1.29 | 25,000 | D | — | — | (F1) The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.27 to $1.29 per share, with a weighted average purchase price of $1.29 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |